Reliability of Magseed® marking before neoadjuvant systemic therapy with subsequent contrast-enhanced mammography in patients with non-palpable breast cancer lesions after treatment: the MAGMA study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Magseed® localization reliably marks breast cancer lesions for surgical excision after neoadjuvant systemic therapy (NAST). Contrast-enhanced spectral mammography (CESM) effectively evaluates treatment response, showing high patient satisfaction.
Area Of Science
- Oncology
- Radiology
- Surgical Oncology
Background
- Neoadjuvant systemic therapy (NAST) is crucial for treating invasive breast carcinoma.
- Accurate localization and excision of residual tumor lesions post-NAST are essential for effective treatment.
- Evaluating treatment response using imaging modalities like contrast-enhanced spectral mammography (CESM) is critical.
Purpose Of The Study
- To evaluate the reliability of using Magseed®, a paramagnetic seed, for localizing residual breast cancer lesions after NAST.
- To assess the utility of CESM in evaluating treatment response following NAST.
- To determine the correlation between imaging-based response and histopathological outcomes.
Main Methods
- An observational, prospective, multicenter study included 109 adult women with invasive breast carcinoma.
- Tumors were marked with Magseed® before NAST and excised using Sentimag® guidance.
- CESM was performed pre- and post-NAST to assess tumor response (RECIST), alongside analysis of surgical and histological data.
Main Results
- Magseed® was successfully retrieved in all surgeries (100%) with no displacement.
- Surgical excision resulted in negative margins in 93.57% of cases, with a low reintervention rate (5.51%).
- CESM-identified RECIST responses strongly correlated with histopathological tumor regression (Miller-Payne grade) and residual lesion size (p < 0.0001).
Conclusions
- Long-term marking of breast cancer lesions with Magseed® is a reliable and feasible method for guiding surgical excision after NAST.
- CESM is a valuable tool for assessing treatment response in conjunction with Magseed® localization.
- The procedure demonstrated high patient satisfaction (98.8%).
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
